Evidence map›Paper›PMID 29632047›Full record

ArticleMolecular & cellular proteomics : MCP2018

Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Elizabeth V Nguyen, Margaret M Centenera, Max Moldovan, Rajdeep Das, Swati Irani, Andrew D Vincent, Howard Chan, Lisa G Horvath, David J Lynn, Roger J Daly and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. DNAJA: emerging targets for anti-tumor therapy.Future oncology (London, England) · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Elizabeth V NguyenFrom the ‡Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Margaret M Centenera¶Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia 5005, Australia.
Max Moldovan‖South Australian Health and Medical Research Institute, Adelaide, South Australia 5000, Australia.
Rajdeep Das¶Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia 5005, Australia.
Swati Irani¶Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia 5005, Australia.
Andrew D Vincent¶Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia 5005, Australia.
Howard ChanFrom the ‡Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
Lisa G Horvath**Cancer Division, The Kinghorn Cancer Centre/Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
David J Lynn‖South Australian Health and Medical Research Institute, Adelaide, South Australia 5000, Australia.
Roger J DalyFrom the ‡Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; roger.daly@monash.edu.
Lisa M Butler¶Adelaide Medical School and Freemasons Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia 5005, Australia.
Freemasons Foundation Centre for Men's Health · AUMonash University · AUUniversity of Adelaide · AUAustralian Regenerative Medicine Institute · AUChris O’Brien Lifehouse · AUFlinders University · AUSouth Australian Health and Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of the heat shock protein 90 (Hsp90) chaperone is a promising therapeutic strategy to target expression of the androgen receptor (AR) and other oncogenic drivers in prostate cancer cells. However, identification of clinically-relevant responses and predictive biomarkers is essential to maximize efficacy and treatment personalization. Here, we combined mass spectrometry (MS)-based proteomic analyses with a unique patient-derived explant (PDE) model that retains the complex microenvironment of primary prostate tumors. Independent discovery and validation cohorts of PDEs (

Indexed as

BenzoquinonesBiomarkers, TumorCell ProliferationCohort StudiesDrug Resistance, NeoplasmHSP90 Heat-Shock ProteinsHumansIsoxazolesLactams, MacrocyclicMaleNeoplasm ProteinsPrincipal Component AnalysisProstatic NeoplasmsProteomeProteomicsReproducibility of Results5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamideBenzoquinonesBiomarkers, TumorHSP90 Heat-Shock ProteinsIsoxazolesLactams, MacrocyclicNeoplasm ProteinsProteomeResorcinolstanespimycinBiomarker: DiagnosticBiomarker: PrognosticCancer therapeuticsex vivoHsp90 inhibitorsPatient cohortspatient-derived explantsProstate cancer biomarkersTumor microenvironment

Identifiers

PMID29632047
PMCPMC6072547
OpenAlexW2797528830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.